IOVA - +80% upside with RR 1:5Set-up perfectly for a continuation and a retest of $18.
Breakout due.
Momentum building.
IOVA trade ideas
IOVA A look at IOVA daily Fib channel levels. Lookin at historical (split adjusted) and current trading levels. Bold channel is current, secondary channel split adjusted. 8.33 key support. Trade above 9.50 very bullish, to $14 liquidity check and higher if breaks out of liquidity box.
IOVA going to hit $28... could be?The stock broke a resistance level yesterday with huge volume
Buy - $12 (yesterday)
Target - $28
Not a recommendation of course
There are always opportunities... you just have to know where to find them (-:
NASDAQ:IOVA
IOVA a volatile medical stock approaches earnings LONGIOVA has doubled in February and broke out above its volume profile high volume area about
one week ago as it runs to earnings. Since it settled down two days ago into a relative side-
ways consolidation. I will take a long trade here for a pre-earnings play to presume that the
buying and bullish momentum will resume nearly immediately.
FDA Grants Approval to Iovance's AMTAGVI for Advanced Melanoma
In a significant stride towards revolutionizing cancer treatment, Iovance Biotherapeutics, Inc. (NASDAQ: NASDAQ:IOVA ) has achieved a monumental milestone. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Iovance's AMTAGVI™ (lifileucel) suspension for intravenous infusion, marking a groundbreaking advancement in the fight against advanced melanoma.
Unveiling a Paradigm Shift in Cancer Therapy:
AMTAGVI™ represents a paradigm shift in cancer therapy, offering a novel approach to treating solid tumor cancers. Unlike conventional treatments, AMTAGVI™ harnesses the power of the body's own immune system by deploying patient-specific T cells known as Tumor-Infiltrating Lymphocytes (TILs). This innovative therapy targets adult patients with unresectable or metastatic melanoma who have previously undergone treatment with a PD-1 blocking antibody and, if applicable, a BRAF inhibitor.
Personalized Precision Medicine:
At the core of AMTAGVI™ lies a personalized precision medicine approach. Through a proprietary process, the therapy collects and expands a patient's unique T cells derived from their own tumor tissue. By returning billions of activated T cells to the body, AMTAGVI™ empowers the immune system to recognize and destroy cancer cells with unprecedented specificity.
Accelerated Approval and Clinical Efficacy:
The FDA's accelerated approval of AMTAGVI™ underscores its remarkable clinical efficacy and potential to address unmet medical needs. Clinical trials, including the pivotal C-144-01 study, demonstrated deep and durable responses in patients with advanced melanoma. Notably, a substantial percentage of patients achieved objective responses, with a median duration of response surpassing 12 months.
Transformative Impact on Patient Care:
For patients grappling with advanced melanoma, AMTAGVI™ offers a ray of hope where conventional treatments have fallen short. With an estimated 8,000 melanoma-related deaths annually in the U.S. alone, the approval of AMTAGVI™ signifies a critical breakthrough in transforming the treatment landscape and improving patient outcomes.
Commitment to Accessibility and Support:
Recognizing the importance of accessibility, Iovance is dedicated to ensuring the widespread availability of AMTAGVI™ through its comprehensive support program, IovanceCares™. This initiative provides patients and Authorized Treatment Centers (ATCs) with invaluable resources, including copay support, financial assistance, and travel accommodations, to facilitate seamless access to therapy.
Conclusion:
In the realm of cancer therapeutics, the approval of AMTAGVI™ marks a historic milestone, heralding a new era of personalized and precision medicine. As Iovance ( NASDAQ:IOVA ) continues its pursuit of addressing unmet medical needs across various solid tumor types, the groundbreaking success of AMTAGVI™ serves as a beacon of hope for patients, clinicians, and researchers alike in the relentless fight against cancer.
IOVA Iovance Biotherapeutics Options Ahead of EarningsAnalyzing the options chain of IOVA Iovance Biotherapeutics prior to the earnings report this week,
I would consider purchasing the 7.5usd strike price Puts with
an expiration date of 2023-6-16,
for a premium of approximately $0.70
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking forward to read your opinion about it.
IOVA - upcoming catalystThis is not a financial advice!
I see first a pullback coming, w8 for it and watch PA closely before entering.
Most info on the chart.
Trade carefully!
IOVA Rising Wedge BreakdownIOVA formed a large bearish Rising Wedge on this Weekly timeframe
This has led to a big downward move, which correlates well with the rising wedge, being a primarily bearish pattern
Support has yet to be found on the Weekly timeframe
Iovance BioTherapeutics (NASDAQ: $IOVA) Popping Pre-market! 🎉Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Iovance Biotherapeutics bearishIovance Biotherapeutics is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte therapies against cancer.
IOVALet's start with a weekly chart (not a logarithm). There are 2 relative bullish divergences, we are also not in a bad zone of the horizontal and inclined trend (depends on whether 2019 candles are considered a puncture). Bearish divergence is also present, but perhaps we will win back it. There are also hidden bulls on the monthly. Fibo levels in chart options hint at a possible bottom. In the logarithm at the level of 0.618, the price.
On the day, almost the same thing, current with noise. We leave the oversold zone by RSI.
A bunch of intermediate targets, since there is a risk of developing a deeper correction for the folding of trend lines, type is 1 of c. Or 5 waves A were formed. And now B. It is difficult to say exactly where it will go, but important and important goals are here.
11/05/21 HC "Wainwright & Co" keeps the purchase 43.0
05/24/21 Oppenheimer keeps outperforming 38.0
IOVA - IOVANCE FINISHED FUELING UP AND ABOUT TO TURN ON ENGINEIovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in the pivotal study in patients with metastatic melanoma and cervical cancer. In addition, the company's TIL therapy is being investigated for the treatment of patients with locally advanced, recurrent or metastatic cancers including head and neck and non-small cell lung cancer. A clinical study to investigate Iovance T cell therapy for blood cancers called peripheral blood lymphocyte (PBL) therapy is open to enrollment.
What an amazing opportunity. RISK 5% REWARD 22% 4.44 RISK TO REWARD RATIO
Enough cash on hand ~$720M cash (9/30/20) to last 3 years of R&D
2021 - Year to get some FDA News - HUGE POTENTIAL MARKET FOR CANCER TREATMENT
Research/ Study showing promise.
Developing Iovance manufacturing facility plans for commercialization 75 Million$ Investment scheduled for completion this year.
IOVAwas a good buy in the 30-32 range but i still think it's a buy here too, institutional interest, everyone likes it, i think it's headed to 40 within a month no prob unless the market tanks, also think it's good long term hold unless the story changes
IOVANCE BIOTHERAPEUTICS Offer Hey traders, IOVANCE BIOTHERAPEUTICS is in a bullish continuation with a large stable buying volume at the end of the session. And she broke the VWAP by force, on the TIMEFRAME 5 Min. It takes off from the same VWAP in the TIMEFRAME 1 Min, we can notice a doji bull candle with a refusal from the buyers. In this situation as at the top of the consolidation zone, it is highly plausible to breakout to land in the next zone.
And join the last preceding higher which is strong level of June, then try to breakout the zone.
Please LIKE & FOLLOW, thank you!
